Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Diacerein: A potential multi-target therapeutic drug for COVID-19

Pedro Gonçalves de Oliveira a,b,⁎, Lara Termíni c, Edison Luiz Durigon d, Ana Paula Lepique e, Andrei Sposito f, Enrique Boccardo d

a Instituto de Ortopedia e Traumatologia, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP 01246-903, Brazil
b Sport Traumatology Group, Department of Orthopaedics and Traumatology, Santa Casa de São Paulo School of Medical Sciences, São Paulo, SP 01221-020, Brazil
c Centro de Investigação Translacional em Oncologia, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP 01246-000, Brazil
d Department of Microbiology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP 05508-900, Brazil
e Laboratório de Biologia Vascular e Aterosclerose (Aterolab), Faculdade de Ciências Médicas da UNICAMP, Campinas, SP 13083-887, Brazil

A R T I C L E  I N F O

Keywords:
Covid-19 treatment
Diacerein
Drug repositioning
Rhein

A B S T R A C T

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 19 (COVID-19), was declared pandemic by the World Health Organization in March 2020. SARS-CoV-2 binds its host cell receptor, angiotensin-converting enzyme 2 (ACE2), through the viral spike (S) protein. The mortality related to severe acute respiratory distress syndrome (ARDS) and multi-organ failure in COVID-19 patients has been suggested to be connected with cytokine storm syndrome (CSS), an excessive immune response that severely damages healthy lung tissue. In addition, cardiac symptoms, including fulminant myocarditis, are frequent in patients in a severe state of illness. Diacerein (DAR) is an anthraquinone derivative drug whose active metabolite is rhein. Different studies have shown that this compound inhibits the IL-1, IL-2, IL-6, IL-8, IL-12, IL-18, TNF-α, NF-κB and NALP3 inflammasome pathways. The antiviral activity of rhein has also been documented. This metabolite prevents hepatitis B virus (HBV) replication and influenza A virus (IAV) adsorption and replication through mechanisms involving regulation of oxidative stress and alterations of the TLR4, Akt, MAPK, and NF-κB signalling pathways. Importantly, rhein inhibits the interaction between the SARS-CoV S protein and ACE2 in a dose-dependent manner, suggesting rhein as a potential therapeutic agent for the treatment of SARS-CoV infection. Based on these findings, we hypothesize that DAR is a multi-target drug useful for COVID-19 treatment. This anthraquinone may control hyperinflammatory conditions by multi-faceted cytokine inhibition and by reducing viral infection.

Introduction

The first case of coronavirus disease 19 (COVID-19), a condition caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in the city of Wuhan in Hubei Province, China, on December 2019. Due to its incubation time (1–14 days) and because it is highly contagious over a short time, infection with SARS-CoV-2 has traversed global borders and caused thousands of deaths, mainly in elderly patients. On March 11th, 2020, the World Health Organization declared COVID-19 a pandemic disease. Even though some infected persons are asymptomatic, SARS-CoV-2 infection can cause severe symptoms, including high fever, severe cough and shortness of breath, which often indicates pneumonia. Severe acute respiratory distress syndrome (ARDS) has been identified as the leading cause of COVID-19-associated mortality. In addition, sepsis, acute cardiac injury, and fulminant myocarditis are common critical complications [1,2].

The mortality related to ARDS as well as multi-organ failure in COVID-19-infected patients may be connected with cytokine storm syndrome (CSS), an excessive immune response that severely damages healthy lung tissue [3]. This response may lead to macrophage activation syndrome (MAS) [4,5] or secondary haemophagocytic lymphohistiocytosis (sHLH) with fulminant and fatal hypercytokinaemia [3,6]. In this scenario, a dilemma emerges due to the potential deleterious effects of immunosuppressive agents used to treat hyperinflammation, such as corticosteroids and Janus kinase (JAK) inhibitors [3], on antimicrobial immunity [7].
Diacerein (DAR), also called diacetylrhein, is an anthraquinone derivative used as a symptomatic slow-acting drug for the management of osteoarthritis (SYSADOA) [8–12] licensed in countries of the European Union, Latin America and Asia for up to 20 years. The drug is administered orally and entirely converted to its active metabolite, rhein, before reaching the systemic circulation [8,12]. The main mechanism of action of DAR is inhibition of the interleukin-1 (IL-1) signalling pathway [8–10,12–20]. In addition, several studies have described the inhibitory effect of this compound on IL-6 [16,20–24] and TNF-α [16,21,25,26]. However, no reported studies have addressed the potential therapeutic use of DAR in patients with COVID-19. Considering the current global health crisis caused by COVID-19, the search for therapeutic alternatives is mandatory. The use of drugs with established mechanisms of action has emerged as a valid tool to identify compounds that can contribute to managing this disease.

**The hypothesis**

SARS-CoV-2 recognizes and binds its host receptor, angiotensin-converting enzyme 2 (ACE2), through the viral spike (S) protein. This binding occurs through the S1 domain of the viral protein, while the S2 domain is responsible for fusion of the viral envelope to the cell membrane [27–29]. Therefore, the level and pattern of human ACE2 expression in different tissues might be critical for differences in susceptibility, symptoms and outcome between different individuals [30]. In addition, it is important to consider that the expression of ACE2, including its related polymorphisms, can differ in the population [30–32]. This enzyme is mainly expressed in endothelial cells of the blood vessels but is also present in other organs, including the heart, lungs and kidneys. This may explain the extra-pulmonary manifestations of the disease as well as some morbidity and mortality factors. At the cellular level, pyroptosis-mediated cell death is strongly involved in the pathophysiology of severe forms of infection with coronaviruses, such as SARS-CoV, MERS-CoV and SARS-CoV-2 (COVID-19), in humans [33]. Oedema and cell membrane rupture are triggered by activation of the NLRP3 inflammasome through the direct action of transmembrane pore-forming viral proteins, such as viroporin 3a. This stimulates the production of gasdermin D (GSDMD) and IL-1β and IL-18 [34]. In addition, cell damage induced by SARS-CoV-2 exposes adjacent cells to damage-associated molecular patterns (DAMPs), activating the NLRP3 inflammasome [35].

The hyperinflammation unleashed during COVID-19 can drive severity [3]. In addition to pulmonary manifestations, CSS-related myocarditis and heart failure should also be considered as important causes of death. The pathophysiology of severe forms of infection with coronaviruses, such as SARS-CoV-2, the therapeutic strategies under study include the use of corticosteroids [3,37,38,59], IL-1 blockade [3,37,38,40], IL-6 blockade [3,37,38], TNF blockade/inhibition [37,38,59] and JAK inhibition [3,37,38,40]. Some of the strategies mentioned, such as the use of vaccines and monoclonal antibodies (MAB), focus on specific targets. On the other hand, other approaches, such as the use of corticoids, present a more nonspecific mechanism of action. It is clear from the data described above that several therapeutic alternatives are under examination. However, at present, no drug for COVID-19 management has been explored from a multi-target perspective.

The active metabolite of DAR, an anthraquinone, is rhein [8,12]. Different studies have demonstrated that the main mechanism of action of DAR is the inhibition of IL-1β production [15,17]. In addition, this drug reduced the number IL-1 receptor (IL-1R) in chondrocytes [15], induced the upregulation of IL-1 receptor agonist (IL-1ra) in cartilage culture [17], and prevented IL-1-induced Nuclear Factor-kB (NF-kB) activation by inhibiting the degradation of its main inhibitor, IκBα [18]. Moreover, rhein was shown to reduce the production of IL-1 converting enzyme (ICE) in cartilage, leading to a reduction in activation of IL-1β from its inactive (pro-IL-1) form [19]. Recently, Chang et al. [60] demonstrated that rhein suppressed caspase-1 protease activity and IL-1β production by interfering with formation of the NLRP3 multi-protein complex. In addition, it may exert its anti-inflammatory action through inhibition of the NF-kB and NALP3 inflammasomes pathways [61,62]. Based on these mechanisms of action, rhein could suppress lung inflammatory injury induced by human respiratory syncytial virus in mice [63]. Finally, the inhibitory effect of this molecule on IL-6 [20–24,64,65] and TNF-α [21,25,26,65] has been reported.

The results from several studies conducted using different experimental approaches suggest that rhein also exerts an inhibitory effect on IL-2 [66], IL-8 [20,65,67,68], IL-12 [66,69] and IL-18 [19,63]. Even though we were unable to find studies addressing the effect of rhein on IL-7, one report showed that chrysophanol, another anthraquinone compound, could reduce the expression of IL-7 receptor α [70].

Different studies have shown that anthraquinones may inhibit the replication of different viruses. For instance, Sun et al. [71] studied the inhibition of hepatitis B virus (HBV) replication by Rheum palmatum ethanol extract in a stable HBV-producing cell line. Although the focus of the study was on R. palmatum extract (RPE), emodin and rhein also showed inhibitory activity against the replication of HBV DNA. Interestingly, at high concentrations, rhein showed higher activity than emodin [71]. Another study showed that rhein significantly inhibited influenza A virus (IAV) adsorption and replication [72]. The authors also observed that rhein decreased IAV-induced oxidative stress and downregulated activation of the TLR4, Akt, p38, JNK MAPK, and NF-κB pathways. Thus, these observations support the potential of rhein as an antiviral agent.

Studies conducted by different laboratories indicate that anthraquinones may inhibit coronavirus activity by targeting different steps of the infection process. First, a study performed by Ho et al. [73] showed that emodin, an anthraquinone compound derived from plants of the genus Rheum and Polygonum, significantly blocked the interaction between the S protein of SARS-CoV and ACE2 in a dose-dependent manner. In addition, this compound inhibited the infectivity of S protein-pseudotyped retrovirus in Vero E6 cells. Considering this, the authors suggested emodin as a potential therapeutic agent for the treatment of SARS-CoV infections. In addition, preincubation of rhein with biotinylated S protein slightly inhibited the interaction between the S protein and ACE2 in a dose-dependent manner [73]. Second, a study conducted by Simmons et al. [74] showed that proteolysis of the viral spike S protein by cathepsin L within endosomes is a critical step in SARS-CoV infection [74]. Interestingly, many cathepsin L inhibitors can inhibit cathepsins B and H [75], which can be explained by the high degree of sequence homology between these proteins [76]. In addition, Savarino et al. [77] demonstrated the effect of rhein on the activity of the human liver enzyme cathepsin B in vitro. Overall, these observations
prompted us to investigate the potential effect of rhein on cathepsin L and on SARS-CoV-2 cell infection.

Finally, alterations in coagulation parameters are associated with a worse prognosis in patients with COVID-19-associated pneumonia [78–80]. Interestingly, rhein was able to protect myocardial H9c2 cells against hypoxia/reoxygenation-induced injury via the AKT/GSK3β/p38 pathway [81]. In addition, many anthraquinones inhibit platelet aggregation [82]. For example, chrysophanol-8-O-glucoside, an anthraquinone derivative in rhubarb, exerts anti-platelet and anti-coagulant activities by inhibiting platelet phosphatidylserine exposure and prolonging the activated partial thromboplastin time. This molecule did not alter prothrombin time or directly inhibit intrinsic factors [83]. Moreover, another study performed with obtusifolin and aurantio-obtusin suggested that these molecules are strong thrombin inhibitors [84]. The data described raise the possibility that rhein, as an anthraquinone, may exhibit similar anti-coagulant effects. This hypothesis warrants further research.

Based on these findings, we hypothesize that DAR is a multi-target drug useful for COVID-19 treatment. This drug may have an impact on viral infection and disease onset, progression and outcome by controlling hyperinflammatory conditions through multi-faceted cytokine inhibition and potentially acting on viral cell infection.

Evaluation of the hypothesis

Effect on pro-inflammatory and anti-inflammatory cytokines

Monolayer cultures of lung, cardiac, endothelial and epidermal cells will be maintained under standard cell culture conditions. The different cell lines will be seeded in 24-well plates and infected with SARS-CoV-2 at different multiplicity of infection (MOI) values. After 48 h, cell cultures will be treated with rhein at different concentrations (1 μM to 400 μM) for 3, 6, 12, 24, 48 and 72 h. Production of the pro-inflammatory and anti-inflammatory cytokines IL-1β, IL-2, IL-6, IL-7, IL-8, IL-10, IL-12, IL-18, IL-37, IL-38 and TNF-α in cell extracts and the supernatants will be measured by ELISA. The expression and function of the NACHT, LRR and PYD domains-containing protein (NALP3) inflammasome in the cell lines treated with rhein will be analysed by Western blotting, flow cytometry, Luminex assay and enzyme-linked immunosorbent assay (ELISA). Additionally, release of the damage-associated molecules APT and HMGB1 in the cell culture supernatants will be measured by ELISA. The expression and function of the NACHT, LRR and PYD domains-containing protein (NALP3) inflammasome in the cell lines treated with rhein will be analysed by Western blotting and RT-polymerase chain reaction (PCR). All the experiments will be performed in triplicate. Moreover, the levels of activated caspase-1 and HMGB1 will be tested.

Effect of rhein on SARS-CoV-2 infection

The effect of rhein-mediated inhibition of the interaction between the S protein and ACE2 on SARS-CoV-2 will be evaluated as described by Ho et al. [73]. The method will consist of purification and biotinylation of recombinant SARS-CoV-2 S protein, biotinylated ELISA, immunofluorescence assay (IFA), and the infection of Vero cells and lung-, cardiac-, endothelial- and epidermal-derived cell lines with S protein-pseudotyped retrovirus. Cell viability will be evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The study will be performed in the presence of rhein at varying concentrations (1 μM–400 μM).

In vivo effect of rhein treatment on virus-induced respiratory syndrome in mice

CS7 Black/6 (7 to 9 weeks old) mice will be infected with the mouse-adapted SARS-CoV-2 MA15 strain [85]. For infection, mice will be intranasally inoculated with 1 × 10⁵ PFU mouse-adapted SARS-CoV-2 in 50 μl of PBS. Treatment of 3 experimental groups and equivalent control and placebo-treated groups with rhein (1 μM to 400 μM) will start at 2, 6 or 12 h after viral inoculation. Body weight and pulmonary function (using a single-chamber, whole-body plethysmograph (Buxco Electronics Inc., NC, USA)) will be assessed daily until the 5th day post-inoculation. At day 5, the blood, lungs, heart, kidneys and peripheral lymph nodes will be harvested after euthanasia. The lungs will be scored for haemorrhage, and the inferior right lobe will be used for viral load determination by Vero E6 cell infection according to the protocol described by Sheahan et al. [86]. For lung damage measurements, the lungs will be fixed and embedded in paraffin. Scores will be given according to the American Thoracic Society scoring tool, which takes into consideration neutrophil infiltration in the alveolar space, neutrophils in the interstitial spaces, hyaline membranes, proteinaceous debris in air spaces, and alveolar septal thickening. Moreover, necrosis, haemorrhagic areas and cellular sloughing will be examined. The hearts and kidneys will also be fixed and embedded for histology to search for necrosis and haemorrhagic areas. The lymph nodes will be mechanically dissociated into single-cell suspensions. Cells will be labelled with Proliferation Cell Dye (BD Biosciences, Carlsbad, CA) and stimulated with 10 mg/ml TPA and 1 μg/ml lonomycin for 4 days. After that period, cell culture supernatants will be harvested for cytokine secretion determination (Th1/Th2/Th17 CBA kit, BD Biosciences, Carlsbad, CA), and cells will be harvested and labelled with anti-CD4, anti-CD8, anti-CD19 and anti-CD25 to determine the proliferation of specific populations. Serum isolated from the blood will be used to determine the cytokine concentration by Luminex and the lactate concentration to evaluate acidosis using a colorimetric assay (Merck/Sigma).

Effect of rhein on SARS-CoV-2 replication

The effect of rhein on SARS-CoV-2 replication will be evaluated as described by Sun et al. [71] with modifications. Briefly, the different cell lines described above will be infected with SARS-CoV-2 virions and cultured in the presence of rhein at different concentrations. After 72 h, the effect of rhein on viral replication will be determined by measuring viral load by quantitative real-time PCR. The expression levels of SARS-CoV-2 surface antigens S and E will be determined by ELISA and a virus neutralization test (VNT) after rhein treatment. Rhein will be tested under the conditions described above. The half-maximal inhibitory concentration (IC50) will be calculated.

Effect of rhein on redox state and major cell signalling pathways in SARS-CoV-2-infected cells

Total extracts from monolayer cell cultures infected with SARS-CoV-2 and treated with rhein under the conditions described above will be analysed using commercially available protein arrays to determine the levels and activation state of proteins involved in the TLR-, Akt-, MAPK-, and NF-kB-regulated signalling pathways. Data will be analysed using ImageJ software. The levels of reactive oxygen species (ROS)/reactive nitrogen species (RNS) will be determined in the total cell extracts and supernatants from monolayer cell cultures infected with SARS-CoV-2 and treated with rhein under the conditions described above.

Anti-platelet aggregation and anti-coagulation activity

In vitro and in vivo platelet aggregation studies will be performed following a previously described method [83]. Platelet-rich plasma (PRP) will be preincubated with rhein at different concentrations for 5 min in the cuvette of an aggregometer before stimulation with aggregating agents (collagen, 2 μg/ml; thrombin, 0.4 U/ml; AA, 100 μM; or ADP, 10 μM). Platelet aggregation will be recorded for 5 min after agonist addition. For in vivo evaluation, the effects of DAR at different concentrations (3, 10, 25, 50 mg/kg) will be compared with those of
aspirin (50 mg/kg). Two hours after oral administration of the drugs, rat blood samples were collected, and platelet aggregation will be monitored as described for the in vitro test. The anti-coagulation activity of rhein will be evaluated by measuring plasma clotting times as previously described [87]. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) will be measured using an Automated Coagulation Laboratory 100 instrument (Instrumentation Laboratory Co.) with platelet-poor plasma (PPP).

Epidemiologic profiles of DAR users

DAR is a symptomatic slow-acting drug for the management of osteoarthritis (SYSADOA), and products based on DAR have been available in the European Union, Latin American and Asian countries for up to 20 years. The optimal dosage is 100 mg/day, administered orally. Considering that age is a risk factor for both diseases, it is very probable that some people infected with SARS-CoV-2 have osteoarthritis and, because of this, eventually use DAR for osteoarthritis management. Thus, prospective and retrospective cohort studies, including other non-interventional studies, constitute a very important tool to test our hypothesis in humans and, based on their results, accelerate the translational development of this potential therapeutic alternative for COVID-19.

Discussion and conclusion

Considering the data presented above, we hypothesize that DAR is a multi-target drug useful for COVID-19 treatment. The mechanisms of action involved include the control of hyperinflammatory conditions by multi-faceted cytokine inhibition of IL-1, IL-2, IL-6, IL-8, IL-12, IL-18 and TNF-α; anti-platelet aggregation activity; and potential effects on viral infection and replication.

Conflict of interest statement

Pedro Gonçalves de Oliveira is responsible for R&D activities at TRB Pharma Indústria Química e Farmacêutica Ltda. TRB Pharma is the owner of the product ARTRODAR®, a diacerein-based product for osteoarthritis treatment.

The other authors declare no conflict of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.mehy.2020.109920.

References

[1] Ruas Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;36:1–3.
[2] Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with COVID-19–infection in Wuhan, China. Cell Death Dis 2020;11(5):293.
[3] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033-4.
[4] Canna SW, Behrens EM. Making sense of the cytokine storm: a conceptual frame-work for understanding, diagnosing, and treating hematopoietic syndromes. Pediatr Clin North Am 2012;59(2):329–45.
[5] Eloseily EM, Cron RQ. Macrophage activation syndrome. In: Ragab G, Atkinson T, Panova E, Jones G. Beneﬁcial effects of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthr Cartil 2010;18(3):289–96.
[6] Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis 2010;2(2):95–104.
[7] Ritchie AJ, Singanayagam A. Immunosuppression for hyperinflammatory conditions by macrophage activation syndrome. J Clin Immunol 2009;29(2):99–107.
[8] Pasin JSM, Ferreira APO, Saraiva ALL, et al. Diacerein decreases TNF-α and IL-18 levels in peritoneal exudates of young rats. Inflamm Res 2009;58(3):189–96.
[9] Douni E, Sifakis PI, Haralambus S, Fernandes P, Kollias G. Attenuation of inﬂammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols. Arthritis Res Ther 2004;6(1):65–72.
[10] Tai W, He L, Zhang X, et al. Characterization of the receptor-binding domain (RBD) of the 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol 2020;18(12):1089–99.
[11] Bartels EM, Bliddal H, Schøndorff EM, Altman RD, Zhang W, Christensen R. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthr Cartil 2010;18(3):289–96.
[12] Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis 2010;2(2):95–104.
[13] Panova E, Jones G. Benefits-risk assessment of diacerein in the treatment of osteoarthritis. Drug Saf 2015;38(3):245–52.
[14] Kim JR, Voo JJ, Kim HA. Therapeutic potential of diacerein in osteoarthritis based on an understanding of its molecular pathogenesis. Int J Mol Sci 2018;19(3):679.
[15] Martel-Pelletier J, Mineau F, Peloquin FC, Cloutier JM, Pelletier JP. In vitro effects of Diacerein and systems IL-1 and TNF-α in human osteoarthritic synovial and chondrocytes. J Rheumatol 1998;25:763–62.
[16] Moore AR, Greenslade KJ, Alam CAS, Willoughby DA. Effects of diacerein on granuloma induced cartilage breakdown in the mouse. Osteoarthr Cartil 1998;6(1):19–23.
[17] Yaron M, Shirazi I, Yaron I. Anti-inflammation: the effect of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthr Cartil 1999;7(7):272–80.
[18] Morales AF, Carmona MM, de Carvalho AP, Lopes MC. Diacerein and rhein prevent interleukin-1β-induced nuclear factor-kappaB activation by inhibiting the degradation of inhibitor kappaB-alpha. Pharmacol Toxicol 2002;91(1):22–8.
[19] Moldovan P, Pelletier J, Jolicoeur FC, Cloutier JM, Martel-Pelletier J. Diacerein and rhein reduce the ICE-Induced IL-1β and IL18 activation in human osteoarthritic chondrocytes. Osteoarthr Cartil 2000;8(3):186–96.
[20] Zhou YY, Xia W, Yue W, Peng C, Rahman K, Zhang H. Rhein: a review of pharmacological activities. Evid Based Complement Altern Med 2015;2015:1–10.
[21] Kaur D, Kaur J, Kamal SS. Diacerein, its beneficial impact on chondrocytes and notable new clinical applications. Braz J Pharm Sci 2018;54(4):e17534.
[22] Steinecker-Frohnwieser B, Kaltenegger H, Weigl L, et al. Pharmacological treatment of rheumatoid arthritis and TNF-α-mediated induction of IL-1, IL-2, IL-6, IL-8, IL-12, IL-18 and TNF-α; anti-platelet aggregation activity; and potential effects on viral infection and replication.

Conflict of interest statement

The other authors declare no conflict of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.mehy.2020.109920.

References

[1] Ruas Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;36:1–3.
[2] Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091.
[3] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033-4.
[4] Canna SW, Behrens EM. Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hematopoietic syndromes. Pediatr Clin North Am 2012;59(2):329–45.
[5] Clossley EM, Cron RJ. Macrophage activation syndrome. In: Ragab G, Atkinson T, Stoll M, editors. The Microbiome in Rheumatic Diseases and Infection. Cham: Springer International Publishing; 2018. p. 151–82.
[6] Tveten H, Aukrust P, Lehne G, Rodrigues JR, Skjensberg OH. Haemopoietic lymphoblastoid cell transformation in COVID-19 cases? Tidsskr Nor Laegeforen 2020;140(6). https://doi.org/10.4055/tidsskr.20.0240.
[7] Ritchie AI, Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? Lancet 2020;395(10229):1111.
[8] Pavlèka K, Brùyère O, Cooper G, et al. Diacerein: benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCCO. Drugs Aging 2016;33(2):75–85.
[9] Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med 2006;166(17):1899–906.
[10] Fidelis TSA, Macedo CR, Maxwell LJ, Fernandes Moça Trevisiani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev 2014;1(8):CD005117.
[11] Rabeen EM, Bliddal H, Schøndorff EM, Altman RD, Zhang W, Christensen R. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthr Cartil 2010;18(3):289–96.
Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with increased morbidity and mortality in COVID-19 patients. Cell Mol Immunol 2020;17(5):541–3.

Clay C, Donati N, Fonmaokong N, et al. Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge. J Virol 2012;86(8):4234–44.

Levi M, van der Poll T. Coagulation and sepsis. Thromb Res 2017;149:38–44.

Schmitt FC, Manolov V, Morgenstern J, et al. Acute kidney injury during sepsis by blocking the toll-like receptor 4 nucleotide factor-κB pathway. Mol Med Rep 2015;12(3):4415–21.

Gupta N, Datta S. Efficacy and safety of diacerein and diclofenac in knee osteoarthritis in Indian patients - a prospective randomized open label study. J Biomed Res 2012;1(1):3.

Yu C, Qi D, Sun JF, Li P, Fan HY. Rhein prevents endotoxin-induced acute kidney injury by inhibiting NF-κB activity. Sci Rep 2015;5:11822.

Palagati C, Villela CA, Vieira KP, Souza GHMF, Hyslop S, Zollner Rde L. Diacerein downregulates proinflammatory cytokines expression and decreases the autocrine diabetes frequency in nonobese diabetic (NOD) mice. Immunopharmacol 2008;6(7):782–91.

Han NR, Kim HY, Kang S, et al. Chrysotherapeut, an anthraquinone from AST2017-01, possesses the anti-proliferative effect through increasing p53 protein levels in human mast cells. Inflamm Res 2019;68(7):569–79.

Li Z, Li LJ, Sun Y, Li J. Identification of natural compounds with anti-hepatitis B virus activity from Rheum palmatum L. ethanol extract. Chemotherapy 2007;53(5):320–6.

Wang QW, Su Y, Sheng JT, et al. Anti-influenza A virus activity of rhein through regulating oxidative stress, TLR4, Akt, MAPK, and NF-κB signal pathways. PLoS ONE 2018;13(1):e0191793.

Hov TY, Wu SL, Chen JG, Li CC, Hsu YC. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antivir Res 2007;74(2):92–101.

Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci U S A 2005;102(33):11876–81.

Raghav N, Jagra S, Kumar A, Bhattacharyya S. Quinazoline derivatives as cathepsin B inhibitors and L inhibitors and cell proliferating agents. Int J Biol Macromol 2012;48:279–286.

Malaguti C, Vilella CA, Vieira KP, Souza GHMF, Hyslop S, Zollner Rde L. Diacerein downregulates proinflammatory cytokines expression and decreases the autocrine diabetes frequency in nonobese diabetic (NOD) mice. Immunopharmacol 2008;6(7):782–91.

Chang WC, Chu MT, Hsu CY, et al. Rhein, an anthraquinone drug, suppresses the expression of proinflammatory cytokines and chemokines. Pharm Res 2012;29(1):135–51.

Rhein inhibits lipopolysaccharide-induced oxidative stress, TLR4, Akt, MAPK, and NF-κB activities. Sci Rep 2015;5:11822.